Photobiomodulation for the Management of Side Effects in Cancer Treatment: WALT Position Statement 2022
August 2022, Faculty of Medicine and Life Sciences, University of Hasselt, Diepenbeek, Belgium
Source: This paper is based on the recommendations of the 12th WALT (World Association of photobiomoduLation Therapy) conference held in Nice from October 3-6, 2018, a follow-up review of existing data, and clinical observations of an international, interdisciplinary panel of clinicians and researchers with expertise in the field.
This report reviews the potential preventive and therapeutic effects of photobiomodulation (PBM) on the side effects of cancer treatments, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).
Conclusion
As recently outlined by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), there is substantial evidence demonstrating the efficacy of PBM in preventing oral mucositis (OM) in specific cancer patient groups.
There is strong evidence for the use of PBM therapy to prevent and treat a wide range of complications in cancer treatment. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided